TONELLA, LUCA
TONELLA, LUCA
SCIENZE MEDICHE
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era
2021-01-01 Avallone, Gianluca; Astrua, Chiara; Fava, Paolo; Tonella, Luca; Mastorino, Luca; Agostini, Andrea; Merli, Martina; Rubatto, Marco; De Pasquale, Rocco; Conti, Luca; Quaglino, Pietro; Ribero, Simone
Alopecia areata after COVID-19 vaccination
2022-01-01 Gallo G.; Mastorino L.; Tonella L.; Ribero S.; Quaglino P.
Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: Experience from an Italian skin cancer unit
2021-01-01 Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Merli M.; Tonella L.; Ribero S.; Fierro M.T.
CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study
2022-01-01 Quaglino P.; Novelli M.; Fava P.; Ortolan E.; Astrua C.; Tonella L.; Tomasini C.F.; Senetta R.; Ribero S.; Ponti R.; Fierro M.T.; Funaro A.
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
2022-01-01 Rubatto, Marco; Sciamarrelli, Nadia; Borriello, Silvia; Pala, Valentina; Mastorino, Luca; Tonella, Luca; Ribero, Simone; Quaglino, Pietro
Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study
2022-01-01 Amabile, Simone; Tonella, Luca; Rubatto, Marco; Argenziano, Giuseppe; Babino, Graziella; Frascione, Pasquale; Dika, Emi; Giacomelli, Luca; Parodi, Aurora; Quaglino, Pietro
Clinical significance of distant metastasis-free survival (Dmfs) in melanoma: A narrative review from adjuvant clinical trials
2021-01-01 Amabile S.; Roccuzzo G.; Pala V.; Tonella L.; Rubatto M.; Merli M.; Fava P.; Ribero S.; Fierro M.T.; Queirolo P.; Quaglino P.
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
2022-01-01 Gullo G.; Rubatto M.; Fava P.; Brizio M.; Tonella L.; Ribero S.; Medri M.; Avallone G.; Mastorino L.; Fierro M.T.; Stanganelli I.; Quaglino P.
Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study
2021-01-01 Barreiro-Capurro A.; Andres-Lencina J.J.; Podlipnik S.; Carrera C.; Requena C.; Manrique-Silva E.; Quaglino P.; Tonella L.; Jaka A.; Richarz N.; Rodriguez-Peralto J.L.; Ortiz P.; Boada A.; Ribero S.; Nagore E.; Malvehy J.; Puig S.
Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience
2020-01-01 Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT.
Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update
2024-01-01 Roccuzzo, Gabriele; Bongiovanni, Eleonora; Tonella, Luca; Pala, Valentina; Marchisio, Sara; Ricci, Alessia; Senetta, Rebecca; Bertero, Luca; Ribero, Simone; Berrino, Enrico; Marchiò, Caterina; Sapino, Anna; Quaglino, Pietro; Cassoni, Paola
Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
2020-01-01 Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T.
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies
2023-01-01 Rubatto Marco; Borriello Silvia; Sciamarrelli Nadia; Pala Valentina; Tonella Luca; Ribero Simone; Quaglino Pietro
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
2021-01-01 Roccuzzo G.; Giordano S.; Fava P.; Pileri A.; Guglielmo A.; Tonella L.; Sanlorenzo M.; Ribero S.; Fierro M.T.; Quaglino P.
Infections in Sézary syndrome: A retrospective cohort study of 113 patients
2022-01-01 Cariti C.; Quaglino P.; Lupia T.; Novelli M.; Marra E.; Fava P.; Caliendo V.; Tonella L.; De Rosa F.G.; Fierro M.T.; Ribero S.
Metastatic melanoma treatment with checkpoint inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit
2020-01-01 Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Agostini A.; Tonella L.; Ribero S.; Fierro M.T.
Nutritional interventions for patients with melanoma: From prevention to therapy—an update
2021-01-01 Pellegrini M.; D'eusebio C.; Ponzo V.; Tonella L.; Finocchiaro C.; Fierro M.T.; Quaglino P.; Bo S.
Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome
2021-01-01 Quaglino P.; Fava P.; Pileri A.; Grandi V.; Sanlorenzo M.; Panasiti V.; Guglielmo A.; Alberti-Violetti S.; Novelli M.; Astrua C.; Rubatto M.; Tonella L.; Berti E.; Pimpinelli N.; Osella Abate S.; Fierro M.T.; Vermeer M.; Scarisbrick J.J.; Ribero S.
Predictive value of baseline [18f]fdg pet/ct for response to systemic therapy in patients with advanced melanoma
2021-01-01 Liberini V.; Rubatto M.; Mimmo R.; Passera R.; Ceci F.; Fava P.; Tonella L.; Polverari G.; Lesca A.; Bello M.; Arena V.; Ribero S.; Quaglino P.; Deandreis D.
Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications
2021-01-01 Tonella L.; Pala V.; Ponti R.; Rubatto M.; Gallo G.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Fava P.; Bertero L.; Senetta R.; Osella-Abate S.; Ribero S.; Fierro M.T.; Quaglino P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era | 2021 | Avallone, Gianluca; Astrua, Chiara; Fava, Paolo; Tonella, Luca; Mastorino, Luca; Agostini, Andrea; Merli, Martina; Rubatto, Marco; De Pasquale, Rocco; Conti, Luca; Quaglino, Pietro; Ribero, Simone | |
| Alopecia areata after COVID-19 vaccination | 2022 | Gallo G.; Mastorino L.; Tonella L.; Ribero S.; Quaglino P. | |
| Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: Experience from an Italian skin cancer unit | 2021 | Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Merli M.; Tonella L.; Ribero S.; Fierro M.T. | |
| CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study | 2022 | Quaglino P.; Novelli M.; Fava P.; Ortolan E.; Astrua C.; Tonella L.; Tomasini C.F.; Senetta R.; Ribero S.; Ponti R.; Fierro M.T.; Funaro A. | |
| Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer | 2022 | Rubatto, Marco; Sciamarrelli, Nadia; Borriello, Silvia; Pala, Valentina; Mastorino, Luca; Tonella, Luca; Ribero, Simone; Quaglino, Pietro | |
| Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study | 2022 | Amabile, Simone; Tonella, Luca; Rubatto, Marco; Argenziano, Giuseppe; Babino, Graziella; Frascione, Pasquale; Dika, Emi; Giacomelli, Luca; Parodi, Aurora; Quaglino, Pietro | |
| Clinical significance of distant metastasis-free survival (Dmfs) in melanoma: A narrative review from adjuvant clinical trials | 2021 | Amabile S.; Roccuzzo G.; Pala V.; Tonella L.; Rubatto M.; Merli M.; Fava P.; Ribero S.; Fierro M.T.; Queirolo P.; Quaglino P. | |
| Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study | 2022 | Gullo G.; Rubatto M.; Fava P.; Brizio M.; Tonella L.; Ribero S.; Medri M.; Avallone G.; Mastorino L.; Fierro M.T.; Stanganelli I.; Quaglino P. | |
| Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study | 2021 | Barreiro-Capurro A.; Andres-Lencina J.J.; Podlipnik S.; Carrera C.; Requena C.; Manrique-Silva E.; Quaglino P.; Tonella L.; Jaka A.; Richarz N.; Rodriguez-Peralto J.L.; Ortiz P.; Boada A.; Ribero S.; Nagore E.; Malvehy J.; Puig S. | |
| Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience | 2020 | Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT. | |
| Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update | 2024 | Roccuzzo, Gabriele; Bongiovanni, Eleonora; Tonella, Luca; Pala, Valentina; Marchisio, Sara; Ricci, Alessia; Senetta, Rebecca; Bertero, Luca; Ribero, Simone; Berrino, Enrico; Marchiò, Caterina; Sapino, Anna; Quaglino, Pietro; Cassoni, Paola | |
| Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient | 2020 | Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T. | |
| Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies | 2023 | Rubatto Marco; Borriello Silvia; Sciamarrelli Nadia; Pala Valentina; Tonella Luca; Ribero Simone; Quaglino Pietro | |
| Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives | 2021 | Roccuzzo G.; Giordano S.; Fava P.; Pileri A.; Guglielmo A.; Tonella L.; Sanlorenzo M.; Ribero S.; Fierro M.T.; Quaglino P. | |
| Infections in Sézary syndrome: A retrospective cohort study of 113 patients | 2022 | Cariti C.; Quaglino P.; Lupia T.; Novelli M.; Marra E.; Fava P.; Caliendo V.; Tonella L.; De Rosa F.G.; Fierro M.T.; Ribero S. | |
| Metastatic melanoma treatment with checkpoint inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit | 2020 | Quaglino P.; Fava P.; Brizio M.; Marra E.; Rubatto M.; Agostini A.; Tonella L.; Ribero S.; Fierro M.T. | |
| Nutritional interventions for patients with melanoma: From prevention to therapy—an update | 2021 | Pellegrini M.; D'eusebio C.; Ponzo V.; Tonella L.; Finocchiaro C.; Fierro M.T.; Quaglino P.; Bo S. | |
| Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome | 2021 | Quaglino P.; Fava P.; Pileri A.; Grandi V.; Sanlorenzo M.; Panasiti V.; Guglielmo A.; Alberti-Violetti S.; Novelli M.; Astrua C.; Rubatto M.; Tonella L.; Berti E.; Pimpinelli N.; Osella Abate S.; Fierro M.T.; Vermeer M.; Scarisbrick J.J.; Ribero S. | |
| Predictive value of baseline [18f]fdg pet/ct for response to systemic therapy in patients with advanced melanoma | 2021 | Liberini V.; Rubatto M.; Mimmo R.; Passera R.; Ceci F.; Fava P.; Tonella L.; Polverari G.; Lesca A.; Bello M.; Arena V.; Ribero S.; Quaglino P.; Deandreis D. | |
| Prognostic and predictive biomarkers in stage iii melanoma: Current insights and clinical implications | 2021 | Tonella L.; Pala V.; Ponti R.; Rubatto M.; Gallo G.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Fava P.; Bertero L.; Senetta R.; Osella-Abate S.; Ribero S.; Fierro M.T.; Quaglino P. |